Relevant bibliographies by topics / Iron in chronic hepatitis C / Books
To see the other types of publications on this topic, follow the link: Iron in chronic hepatitis C.

Books on the topic 'Iron in chronic hepatitis C'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 45 books for your research on the topic 'Iron in chronic hepatitis C.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Ozaras, Resat, and Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shiffman, Mitchell L., ed. Chronic Hepatitis C Virus. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1192-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

National Digestive Diseases Information Clearinghouse (U.S.). Chronic hepatitis C: Current disease management. Bethesda, MD]: National Digestive Diseases Information Clearinghouse, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shih, Chiaho. Chronic hepatitis B and C: Basic science to clinical applications. New Jersey: World Scientific, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Foster, Graham. Management of Chronic Viral Hepatitis. London: Taylor & Francis Group Plc, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

D, Goldin R., ed. Management of chronic viral hepatitis. London: Martin Dunitz, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2009, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Takahashi Memorial Forum (1995 Tokyo, Japan). Interferon therapy on chronic hepatitic C: Proceedings of the "Takahashi Memorial Forum", held in Tokyo, Japan on 25 November 1995. Edited by Takahashi Tadao 1908-, Yamanaka Masami, Okabe Kazuhiko, and Toda Gotaro. Amsterdam: Elsevier, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

San Francisco (Calif.). Dept. of Public Health. Communicable Disease Control Unit. Registry match: Chronic hepatitis B, hepatitis C infection and HIV : 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Anand, Narasimhan R., ed. 100 questions and answers about hepatitis C: A Lahey Clinic guide. Sudbury, Mass: Jones and Bartlett Publishers, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Everson, Gregory T. Living with hepatitis c: A survivor's guide. 5th ed. New York: Hatherleigh, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Fabry, Stephen. 100 questions & answers about hepatitis C: A Lahey Clinic guide. Sudbury, Mass: Jones and Bartlett Publishers, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Husereau, Donald Robert. Interferon-based therapies for chronic hepatitis C virus infection: An assessment of clinical outcomes. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Dammacco, Franco. HCV Infection and Cryoglobulinemia. Milano: Springer-Verlag Italia, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Ozaras, Resat, and Dominique Salmon-Ceron. Viral Hepatitis: Chronic Hepatitis C. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

A, Gebo Kelly, United States. Agency for Healthcare Research and Quality., and Johns Hopkins University. Evidence-based Practice Center., eds. Management of chronic hepatitis C. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Shih, Chiaho. Chronic Hepatitis B and C. WORLD SCIENTIFIC, 2011. http://dx.doi.org/10.1142/7695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), ed. Chronic hepatitis C: Current disease management. [Bethesda, MD]: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) and National Digestive Diseases Information Clearinghouse (U.S.), eds. Chronic hepatitis C: Current disease management. [Bethesda, MD]: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Chronic Viral Hepatitis. Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), ed. Chronic Hepatitis C, Current Disease Management, March 2003. [S.l: s.n., 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

1944-, Gerlich W. H., ed. Research in chronic viral hepatitis. Wien: Springer-Verlag, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Progress in Hepatology 2 - Interferon Therapy on Chronic Hepatitis C. Elsevier Science Pub Co, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Foster, Graham. Management of Chronic Viral Hepatitis. Taylor & Francis, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Honegger, Jonathan R. Hepatitis C Virus. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0005.

Full text
Abstract:
An estimated 185 million individuals have been infected with hepatitis C virus (HCV) worldwide. Although often clinically silent for decades, chronic HCV infection predisposes to late-onset complications, including liver cirrhosis and hepatocellular carcinoma. Mother-to-child transmission (MTCT) of HCV affects approximately 5% of children born to viremic mothers and is the primary route of HCV infection in young children. While some vertically acquired HCV infections are resolved during the first years of life, many persist indefinitely. Chronically infected children tend to be asymptomatic and have mild liver disease, but they face a risk of progression to advanced liver disease in adulthood. Current diagnostic and management strategies leave most infected children undiagnosed and untreated. Widespread use of newly-available direct-acting antiviral therapies has the potential to substantially reduce the global burden of HCV, including vertically acquired HCV, but an effective vaccine likely will be required to achieve this ultimate goal.
APA, Harvard, Vancouver, ISO, and other styles
27

McCarthy, Shaun A. Management for Chronic Hepatitis C (Evidence Report/Technology Assessment). Agency, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Gordon, Richard. Management of Chronic Viral Hepatitis (Manufacturing Engineering and Materials Processing). Informa Healthcare, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Chronic Hepatitis C Virus Advances In Treatment Promise For The Future. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

National Institute of Health (U.S.), ed. Alpha interferon found to be effective treatment for chronic hepatitis C. Bethesda, Md: National Institutes of Health, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Price, Jennifer Cohen, Priyanka Amin, and Antoine Douaihy. Hepatitis C and HIV Co-Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0043.

Full text
Abstract:
Chronic infection with hepatitis C virus (HCV) is a leading cause of end-stage liver disease and is the most common indication for liver transplantation in the United States. Because of shared risk factors, individuals living with HIV infection are disproportionately affected by HCV. Moreover, co-infection with HIV accelerates the natural history of chronic HCV infection, increasing the risk of cirrhosis, hepatocellular carcinoma, hepatic decompensation, and death. Highly effective medications such as direct-acting antivirals (DAA) to cure HCV are now available and have the potential to profoundly improve the health of HIV-HCV-co-infected individuals. However, addressing the many gaps in the HCV care cascade is necessary to fully achieve the benefits of these drugs. This chapter reviews the natural history of HIV-HCV co-infection, the psychiatric comorbidities associated with HCV infection, the evolution of HCV treatment, and the barriers to care that HIV-HCV-co-infected individuals continue to face.
APA, Harvard, Vancouver, ISO, and other styles
32

Fabry, Stephen. 100 Q&A About Hepatitis C: A Lahey Clinic Guide (100 Questions & Answers about . . .). Jones and Bartlett Publishers, Inc., 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Viral Hepatitis Mapping Project National Report 2017: Geographic Diversity in Chronic Hepatitis B and C Prevalence, Management and Treatment. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Bruce, Brady, and Canadian Agency for Drugs and Technologies in Health., eds. Pegylated interferon combined with ribavirin for chronic hepatitis c virus infection: An economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Wilson, Deanna. Hepatitis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199976805.003.0035.

Full text
Abstract:
Hepatitis A (HAV) and E (HEV) viruses are spread via the fecal-oral route. Hepatitis B virus (HBV) exposure is via occupational or recreational activities. Hepatitis D virus (HDV; also spread parentally) can only coinfect or superinfect those with chronic HBV. Hepatitis C (HCV) transmission is predominantly parenteral; the highest risk group is injection drug users. Prodromal-period patients with acute hepatitis present with vague constitutional symptoms when serum transaminases peak, with elevated serum bilirubin and varying levels of hepatic protein synthesis impairment; during the icteric phase, patients develop abdominal pain, hepatomegaly, and jaundice. Acute hepatitis has limited therapy; treatment is predominantly supportive. However, most adults with acute phase HAV, HBV, HDV, and HEV spontaneously clear the virus. Most individuals with HCV develop chronic hepatitis. Patients with known HAV, HBV, or HEV exposures may be eligible for post-exposure prophylaxis to reduce their risk of infection.
APA, Harvard, Vancouver, ISO, and other styles
36

Keshav, Satish, and Palak Trivedi. Viral hepatitis. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0212.

Full text
Abstract:
Hepatitis means ‘inflammation of the liver’ and is manifest with symptoms that include malaise, anorexia, fever, flu-like symptoms, and pain in the right upper quadrant of the abdomen, with the pain being caused by swelling of the liver and its capsule. Elevations in circulating hepatic enzymes, particularly aspartate transaminase and alanine transaminase, are common, with jaundice occurring some time after the onset of other symptoms and signs. There are five viruses that primarily cause viral hepatitis: hepatitis A, B, C, D, and E viruses, abbreviated HAV, HBV, HCV, HDV, and HEV, respectively. These viruses are all hepatotrophic, in that the liver is the primary site of infection. HAV, HBV, and HEV are usually acute, self-limiting infections that may, nonetheless, cause morbidity and, in the case of HEV, fatality. However, HBV and, more so, HCV can cause chronic carriage of the virus over many years, as well as the development of chronic hepatitis. HDV is only pathogenic in conjunction with HBV. After recovery from acute infection with HAV, individuals have long-lasting immunity against further infection. The same holds true for the majority of individuals with acute HBV infection. There seems to be little natural immunity to HCV infection, and a significant proportion of cases result in chronic hepatitis. Immunity to HEV is not long-lasting, and repeated infections are possible. Many other viruses can cause hepatitis, of which cytomegalovirus, herpes simplex virus, Epstein–Barr virus, and flaviviruses such as dengue and yellow fever are the most important. The liver, however, is not their primary site of replication or cellular damage.
APA, Harvard, Vancouver, ISO, and other styles
37

(Editor), H. Kumada, Y. Miyakawa (Editor), and S. Lino (Editor), eds. Chronic Hepatitis C in Asia: Epidemiology, Pathophysiology, Hepatocellular Carcinoma And Treatment: 2nd Mmrf Meeting on Viral Hepatitis in Asia, Tokyo, May 2004: Proceedings (Intervirology). Not Avail, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Locke, Kenneth Andrew. Descriptive evaluation of the section 8 process for interferon treatment of patients with chronic hepatitis C in Ontario. 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Van Calsteren, Kristel. Chronic maternal infections. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713333.003.0050.

Full text
Abstract:
Pregnant women diagnosed with chronic infections are a worldwide problem. In developed countries, the most frequently encountered are hepatitis B and C, toxoplasmosis, syphilis, herpes simplex, and Cytomegalovirus infections. In developing countries, human immunodeficiency virus and malaria are also seen commonly in pregnant women. Maternal infections are associated with various complications in pregnant women, but also with congenital infections with or without structural anomalies and long-term sequelae, fetal growth restriction, preterm delivery, and perinatal mortality. Moreover, increasing evidence suggests that maternal infection during pregnancy affects the developing immune system of the fetus independently of the vertical transmission of pathogens. This chapter discusses the pathogen characteristics, ways of transmission, clinical presentation, diagnostic options, treatment, and, if relevant, prophylaxis for the most common infections in pregnant women (excluding hepatitis which is discussed elsewhere).
APA, Harvard, Vancouver, ISO, and other styles
40

J, Shepherd, and National Co-ordinating Centre for HTA (Great Britain), eds. Pegylated interferon [alpha]-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Tunbridge Wells: Gray Publishing on behalf of NCCHTA, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

Dammacco, Franco. HCV Infection and Cryoglobulinemia. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
42

Thomas London, W., Jessica L. Petrick, and Katherine A. McGlynn. Liver Cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0033.

Full text
Abstract:
Primary liver cancer is the sixth most frequently occurring cancer in the world and the second most common in terms of cancer deaths. The global burden of liver cancer is borne principally by countries in East Asia and Africa, where 80% of liver cancer arises. Incidence rates of liver cancer, however, have begun to decline in Asia, while rates are increasing in low-rate areas such as Europe and North America. The dominant histology of liver cancer in almost all countries is hepatocellular carcinoma (HCC). The major risk factors for HCC—chronic infection with either hepatitis B virus (HBV) or hepatitis C virus (HCV), aflatoxin B1 (AFB1) contamination of foodstuffs, excessive alcohol consumption, and diabetes/obesity/fatty liver disease—all result in chronic inflammation in the liver. HBV infection is preventable by immunization, and HCV infection is largely preventable by public health measures and now is curable with new antiviral therapies.
APA, Harvard, Vancouver, ISO, and other styles
43

Winston, Jonathan, Etti Zeldis, John A. Grimaldi, and Esteban Martínez. HIV-Associated Nephropathy, End-Stage Renal Disease, Dialysis, and Kidney Transplant. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0044.

Full text
Abstract:
Antiretroviral therapy has changed the phenotype of HIV-related kidney disease to a more chronic disease model. In addition to HIV-associated nephropathy (HIVAN), patients with HIV may experience kidney dysfunction related to other chronic illnesses, such as diabetes, hypertension, and hepatitis C. Patients with HIV should be monitored for the development of chronic kidney disease and the potential nephrotoxicity of antiretroviral therapy. For patients with HIV who progress to end-stage renal disease, the outcomes on dialysis and management of the dialysis procedure are similar to the outcomes of patients without HIV. Renal transplantation is a promising treatment option for HIV patients with end-stage renal disease, despite certain barriers inherent in the transplant evaluation process. Concomitant HIV and end-stage renal disease, with the stress of dialysis, can exacerbate psychiatric illness.
APA, Harvard, Vancouver, ISO, and other styles
44

Franceschi, Silvia, Hashem B. El-Serag, David Forman, Robert Newton, and Martyn Plummer. Infectious Agents. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0024.

Full text
Abstract:
Eleven infectious agents (seven viruses, three parasites, and one bacterium) have been classified by the International Agency for Research on Cancer as carcinogenic to humans for one or more cancer sites: hepatitis B virus; hepatitis C virus; thirteen types of human papillomavirus (HPV); human immunodeficiency virus type 1 (HIV-1); human T-cell leukemia virus type 1; Epstein-Barr virus; Kaposi sarcoma herpesvirus; Helicobacter pylori; Opisthorchis viverrini; Clonorchis sinensis; and Schistosoma haematobium. Other infectious agents, such as Merkel cell polyomavirus, Plasmodium falciparum, and cutaneous HPVs, have been classified as “probably carcinogenic” or “possibly carcinogenic.” Accurate biomarkers of chronic infection have been essential for estimating risk and ascribing a causal role to infectious agents in cancer. Of the 14 million cases of cancer estimated to have occurred worldwide in 2012, 2.2 million were caused by infectious agents. Vaccination and screen-and-treat programs have the potential for greatly reducing the burden of cancer caused by infections.
APA, Harvard, Vancouver, ISO, and other styles
45

Cooke, Graham. Viral infection. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0308.

Full text
Abstract:
Viral infection includes any clinical illness caused by a pathogenic virus. Acute viral infections are amongst the most common illnesses of humans and range from minor upper respiratory tract infections to viral haemorrhagic fever. The principles in diagnosing acute viral infection are, first, recognize the syndrome, then identify key features that might suggest a specific diagnosis, and, finally, consider laboratory investigations to elucidate the specific causative agent. The host–pathogen response determines different outcomes for specific viral infections. After infection with some viruses (e.g. measles virus, rubella virus) protective immunity develops, there is no latency or chronic carriage, and reinfection is prevented. Another group of viruses, in the presence of inadequate immune response, can cause chronic infection (e.g. hepatitis B and C viruses). This chapter reviews the clinical features, diagnosis, and management of acute viral infections in immunocompetent individuals.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Iron in chronic hepatitis C' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography